Eli Lilly reported updated late-stage trial results showing its breast cancer drug Imlunestrant improved survival and delayed disease progression. Among patients with ESR1 mutations, the drug cut the risk of worsening or death by 38% versus standard therapy. Median survival reached 34.5 months, about 11 months longer, though not statistically conclusive.